Prominent Players - Metoprolol Tartrate Industry

The use of beta blockers like metoprolol tartrate is anticipated to rise due to the rising prevalence of hypertension, which is anticipated to fuel market expansion over the projection period. Over the course of the forecast period, market participants are anticipated to launch more products, fueling the development of the global metoprolol tartrate market. For instance, on April 11, 2016, Mylan N.V., a manufacturer of specialty drugs and generic medications, announced the introduction of Metoprolol Tartrate Tablets United States Pharmacopeia (USP), a standard dosage of a drug substance or ingredient in the form of 37.5 mg tablets and 75 mg tablets, which is the generic version of Lopressor Tablets created by Novartis. These new strengths of 37.5 mg and 75 mg tablets will be a fresh entry into the metoprolol tartrate market as Metoprolol Tartrate Tablets USP strengths are already available in forms of 25 mg, 50 mg, and 100 mg.

The global Metoprolol Tartrate Market is estimated to be valued at US$ 6,101.4 Mn in 2022 and is expected to exhibit a CAGR of 3.3% over the forecast period (2022-2030).

Key Companies in the Metoprolol Tartrate Industry:

Novartis Pharmaceuticals Canada Inc.

The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. On March 2022, Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy. Novartis in December, 2022 announced the European Commission (EC) approved Pluvicto® (INN: lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand therapy.

AstraZeneca Pharma India Limited

AstraZeneca India was established in 1979 and is headquartered at Bengaluru, Karnataka. In August, 2022 AstraZeneca India announced its partnership with Alveofit, a SaaS-IoT enabled respiratory healthcare platform, to offer IoT enabled handheld spirometers at hospitals across the country.

Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and others segments.  Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.  Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. On Feb 2021, Dr. Reddy’s Laboratories has introduced an orally disintegrating formulation of lansoprazole to the U.S. market. Lansoprazole is a proton pump inhibitor, a mechanism of action designed to reduce the amount of acid made in the stomach and thereby treat conditions including indigestion, heartburn, acid reflux and gastroesophageal reflux disease.

Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company was founded in 1983 and is based in Mumbai, India.

Ipca Laboratories Ltd.

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company was incorporated in 1949 and is based in Mumbai, India.

Aurobindo Pharma Ltd.

Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India.  Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.

Hikma Pharmaceuticals PLC.

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company was founded in 1978 and is based in London, the United Kingdom. In January, 2023 Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new exclusive licensing agreement with Celltrion Healthcare Co., Ltd, a global biopharmaceutical company.

*Definition-

Metoprolol tartrate is a medication used to treat high blood pressure, also referred to as hypertension.